. 2016 Sep 19;7(45):72868–72885. doi: 10.18632/oncotarget.12108

Table 2. Effect of D16F7 mAb treatment on tumor growth in vivo.

Experimental group^a	Tumor volume inhibition (%)^b^,^d	Tumor growth quadrupling time (days)^c^,^d	Tumor growth delay index^d
Control mice	–	3.37 ± 0.16	–
10 mg/kg D16F7	48.6 ± 9.7	5.18 ± 0.27	1.54 ± 0.08
20 mg/kg D16F7	74.4 ± 15.0	7.63 ± 1.11	2.26 ± 0.33

Mice were treated with vehicle (control mice) or 10 or 20 mg/kg D16F7 mAb on alternate days. D16F7 antitumor efficacy was assessed by the end-points described in the Materials and methods section.

Tumor growth inhibition was calculated at the end of the experiment illustrated in Figure 5, on day 16 after injection of B16F10 melanoma cells (n = 5 animals/group).

Tumor growth quadrupling time was calculated starting from day 6 (n = 8 animals/group).

Results are mean values ± SD. Statistical analysis using the ANOVA and Bonferroni post-test method for multiple comparisons indicated that differences between tumor growth quadrupling times of treated (both 10 and 20 mg/kg) and control mice were statistically significant (p < 0.05). Differences in tumor volume inhibition, tumor growth quadrupling time and tumor growth delay index between 10 and 20 mg/kg treated mice were statistically significant (p < 0.05). Data shown are representative of two independent experiments with similar results.